MYELODYSPLASTIC SYNDROME

This study tests a refined cord blood transplant method for people with hard-to-treat blood cancers like leukemia and lymphoma. Participants receive chemotherapy and radiation before the transplant to kill cancer cells and prepare the body, then donor stem cells are infused to re…

This study tests a two-step method using lower doses of radiation and chemotherapy before a stem cell transplant for people with various blood cancers or bone marrow failure. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About…

This early-phase study tests a new drug called FHD-286 combined with two standard chemotherapy drugs (decitabine and venetoclax) in adults with acute myeloid leukemia (AML) that is high-risk or has returned after treatment. The main goals are to find the safest dose and watch for…

This study tests whether adding venetoclax to a standard chemotherapy regimen (FLAG IDA) helps more people with newly diagnosed acute myeloid leukemia (AML) achieve deep remission. About 102 adults aged 18 to 65 will be randomly assigned to the new combo or standard treatment. Th…

This early-phase trial tests whether combining two drugs—tagraxofusp and azacitidine—can safely prevent cancer from returning after a donor stem cell transplant in people with CD123-positive acute myeloid leukemia or myelodysplastic syndrome. About 43 adults aged 18 to 75 will re…

This study is testing a combination of three drugs—quizartinib, decitabine, and venetoclax—in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The goal is to see if the combination can shrink or control the cancer. The trial is for adults 60 and old…

This early-phase trial tests whether adding emapalumab to standard medications can safely prevent graft-versus-host disease (GVHD) in 15 adults with leukemia or myelodysplastic syndrome receiving a reduced-intensity donor stem cell transplant. Emapalumab blocks a protein that dri…

This study compares two strategies to lower the risk of graft-versus-host disease (GVHD) in people with acute leukemia or myelodysplastic syndrome (MDS) who are getting a donor stem cell transplant. Participants will receive either a treatment that removes certain immune cells fr…

This study tests a combination of drugs to help people with aplastic anemia or low-risk myelodysplastic syndrome (MDS) who have dangerously low blood counts. The treatment includes horse anti-thymocyte globulin (hATG) and cyclosporine to calm the immune system, plus steroids and …

This study tests a new drug called elritercept against a standard treatment (epoetin alfa) for anemia caused by a bone marrow disorder called myelodysplastic syndromes (MDS). About 300 adults who need regular red blood cell transfusions will take part. The goal is to see if elrit…

This study is for people with certain blood cancers (like leukemia) that have a specific genetic change called an IDH1 mutation. It tests a combination of two or three drugs: ivosidenib (targets the mutation), venetoclax (blocks a protein that helps cancer cells survive), and som…

This early-phase study tests a new drug, SL-401, combined with standard treatments (azacitidine and venetoclax) for people with certain blood cancers like acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The g…

This early-stage study is testing a new drug called RPT1G in 24 people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) whose cancer has returned or not responded to standard treatments. The main goals are to check if RPT1G is safe and to find the be…

This study tests a combination of two drugs, enasidenib and azacitidine, for people with a specific genetic form of acute myeloid leukemia (IDH2-mutated) that has come back or stopped responding to treatment. The goal is to see if the combo can shrink or control the cancer. About…

This study tests whether adding the drug ruxolitinib to the usual two-drug regimen (tacrolimus and methotrexate) can better prevent graft-versus-host disease (GVHD) in children and young adults (ages 2-22) undergoing bone marrow transplant for leukemia or myelodysplastic syndrome…

This study tests whether giving a chemotherapy drug (decitabine) along with a JAK inhibitor (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPNs) get to transplant and have better outcomes. About 25 a…

This early-phase trial is testing whether the drug olutasidenib can safely prevent blood cancers (AML, MDS, or CMML) from coming back after a donor stem cell transplant. The study includes 15 adults whose cancers have a specific IDH1 gene change. Participants will take olutasiden…

This study tests a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) in about 500 adults with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blast-phase chronic myeloid leukemia. The goal is to see how well these drugs kil…

This study tests a combination of two drugs, CPX-351 and ivosidenib, in about 30 people with a specific genetic form of acute myeloid leukemia or a related high-risk bone marrow disorder. The goal is to see if the combo can shrink or control the cancer. Participants must have the…

This study tests whether giving patients their own specially matched natural killer (NK) cells after chemotherapy and a cord blood transplant can help keep blood cancers like leukemia and lymphoma from coming back. About 100 adults with various blood cancers will receive NK cells…

This study tests a drug called canakinumab in people with low- or intermediate-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). The drug is an antibody that may slow cancer growth. About 76 adults will receive injections to see if it improves blood c…

This early-stage trial tests a new drug called SEA-CD70, alone or with other medicines, in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goals are to find safe doses and check for side effects. About 178 adults whose cancer has returned or n…

This early-phase study tests whether adding a radioactive antibody (225Ac-DOTA-daratumumab) to standard chemotherapy and radiation before a donor stem cell transplant is safe and effective for people with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, or myelodys…

This early-phase trial tests a combination of three drugs (pembrolizumab, decitabine, and venetoclax) in adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to prior treatment. The goal is to find the safest dose and see how well the …

This early-stage study tests whether drugs that remove extra metals from the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. Researchers want to find the safest dose and see if lowering metal levels in blood…

This early-stage study tests a new type of stem cell transplant for children whose blood cancer or solid tumor has returned or is hard to treat. Doctors use a special method to remove certain immune cells from the donor's stem cells, then give a drug called zoledronate after tran…

This study tests whether adding enasidenib to standard chemotherapy (ASTX727) improves outcomes for people with a high-risk form of myelodysplastic syndrome (MDS) that has a specific IDH2 gene mutation. About 54 participants will be randomly assigned to receive either the standar…

This study tests a stem cell transplant from a half-matched donor for people with blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare the body. The goal is to see if this approach helps the new stem cells grow and fight cancer wit…

This study tests a drug called SP-420 in people with two blood disorders—beta thalassemia and low-risk myelodysplastic syndromes—who need regular blood transfusions. Transfusions can cause dangerous iron buildup in organs. The drug aims to safely remove that extra iron. About 90 …

This early-stage study tests a new drug called cirtuvivint, alone or with another drug (ASTX727), in people with certain blood cancers (MDS and AML). The goal is to find a safe dose and see how well it works. About 54 adults whose cancer has returned or not responded to treatment…

This study tests a combination of three drugs (ASTX727, venetoclax, and gilteritinib) for people with acute myeloid leukemia or high-risk myelodysplastic syndrome that has a specific gene change called FLT3. The goal is to find the best dose and see how well the drugs work togeth…

This study tests a new device that filters excess iron from the blood in people with myelodysplastic syndrome (MDS) or myelofibrosis who cannot take standard iron-removing medications. Participants will undergo three short dialysis-like sessions over one week. The goal is to see …

This study tests a treatment for adults aged 60 and older with newly diagnosed, high-risk acute myeloid leukemia (AML) or similar blood cancers. The approach combines strong chemotherapy (FLAG-Ida) with a donor stem cell transplant shortly after, aiming to shorten the dangerous p…

This early-phase study tests a new drug called rezatapopt combined with azacitidine in people with a specific genetic mutation (TP53Y220C) linked to acute myeloid leukemia or myelodysplastic syndrome. The goal is to see if the combination is safe and can help control the disease …

This early-phase trial tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize an…

This early study tests a new drug called BMS-986497 in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer has returned or not responded to other treatments. The drug is given alone or together with standard medicines (azacitidine and venetocla…

This early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…

This study tests whether adding venetoclax to standard chemotherapy before a stem cell transplant can help people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) live longer without their cancer coming back. About 324 adults aged 18 to 70 will receiv…

This early-phase study tests a new stem cell treatment called Orca-T, combined with targeted radiation and chemotherapy, for people aged 60-75 with acute leukemias or myelodysplastic syndrome (MDS). The goal is to find the safest dose and see how well the body tolerates the treat…

This study tests a two-step method of giving an anti-rejection drug (ATG) along with standard medications to prevent severe graft-versus-host disease (GVHD) in people with blood cancers receiving a stem cell transplant. About 56 adults aged 18-75 will participate. The goal is to …

This study tests whether giving a CMV vaccine to stem cell donors can protect transplant recipients from CMV infection. Donors receive the vaccine before donating stem cells, and the immunity is passed to the patient. The trial involves 216 people with blood cancers and aims to r…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after transplant. About 46 people with various blood cancers or disorders will take part. The goal i…

This study compares giving cancer treatment at home versus in a clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves the overall experience. About 220 participants will be randomly assigned to receive their t…

This study tests whether giving cancer treatment at home is preferred over going to a clinic. It involves 27 adults with various cancers in the Florida Panhandle. The goal is to see if home care improves patient satisfaction and is safe.

This study is testing whether a curcumin supplement (the active ingredient in turmeric) can lower inflammation and improve symptoms in people with certain blood disorders, including low-risk myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). About 30 adults wi…

This study is a long-term observation of 1,000 patients receiving stem cell transplants for blood diseases at a hospital on the Qinghai-Tibet Plateau. Researchers will collect information on patient health, treatment results, and costs to understand how high altitude affects reco…

This study collects tissue and fluid samples (like blood, urine, and tumor tissue) from up to 5,000 children and adults with cancer at the NIH Clinical Center. The samples are used for research only, not for direct treatment. The goal is to help scientists learn more about cancer…

This study is creating a large database of people with various blood diseases in China, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, out…

This study is for people with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS). It uses special lab tests to find tiny amounts of cancer cells that may remain after treatment. The goal is to see if these tests can predict who is at higher risk of the dise…

This study screens children and young adults (under 22) with leukemia that has returned or is difficult to treat. By analyzing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to …

This study is for adults with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have not yet received treatment. Researchers will test blood and bone marrow samples for specific biomarkers to see if participants can join a treatment trial that tar…

This study looks at people with neuroendocrine tumors (NETs) who are getting or have gotten peptide radionuclide therapy (PRRT). The goal is to find early warning signs in the blood that might show who is at higher risk of developing blood cancers like myelodysplastic syndrome (M…